You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 108 No. 5, May 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  LABORATORY SCIENCES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Effect of Topically Administered Epidermal Growth Factor on Corneal Wound Strength

Howard M. Leibowitz, MD; Sergio Morello, Jr, MD; Michael Stern, PhD; Allan Kupferman, PhD

Arch Ophthalmol. 1990;108(5):734-737.


Abstract

• A 9-mm perforating corneal wound was created in one eye of New Zealand albino rabbits, sutured, and treated with mouse-derived epidermal growth factor (1 mg/L), human-derived epidermal growth factor (1.0 mg/L to 100 mg/L), or buffered saline, instilled once, twice, or four times daily. Both mouse-derived epidermal growth factor and human-derived epidermal growth factor significantly increased the tensile strength of full-thickness corneal wounds after 9 days of topical therapy. For human-derived epidermal growth factor, a concentration of 10 mg/L administered twice daily produced the maximal effect. An increase in either the concentration of epidermal growth factor or its frequency of administration failed to induce a further increase in wound strength. Indeed, at a concentration of 100 mg/L, human-derived epidermal growth factor appeared to lose its ability to accelerate healing of full-thickness corneal wounds.



Author Affiliations

From the Departments of Ophthalmology (Drs Leibowitz, Morello, and Kupferman) and Pharmacology (Dr Kupferman), Boston (Mass) University School of Medicine; and Alcon Laboratoratories, Inc, Fort Worth, Tex (Dr Stern).


Footnotes

Accepted for publication on December 20,1989.

Reprint requests to Boston University School of Medicine, 80 E Concord St, Boston, MA 02118 (Dr Leibowitz).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Epidermal Growth Factor Synergism with TGF-{beta}1 via PI-3 Kinase Activity in Corneal Keratocyte Differentiation
He and Bazan
IOVS 2008;49:2936-2945.
ABSTRACT | FULL TEXT  

Growth factors but not gap junctions play a role in injury-induced Ca2+ waves in epithelial cells
Klepeis et al.
J. Cell Sci. 2001;114:4185-4195.
ABSTRACT | FULL TEXT  

Influence of topical human epidermal growth factor on postkeratoplasty re-epithelialisation
Dellaert et al.
Br J Ophthalmol 1997;81:391-395.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.